Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study
Abstract Background and Aims The prognosis of intrahepatic cholangiocarcinoma (ICC) after radical resection is far from satisfactory; however, the clinical value of adjuvant therapy (AT) remains controversial. This multicenter study aimed to evaluate the clinical value of AT and identify potential p...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2925 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849330505756966912 |
|---|---|
| author | Lei Wang Manjun Deng Qiao Ke Jianying Lou Shuguo Zheng Xinyu Bi Jianming Wang Wei Guo Fuyu Li Jian Wang Yamin Zheng Jingdong Li Shi Cheng Weiping Zhou Yongyi Zeng |
| author_facet | Lei Wang Manjun Deng Qiao Ke Jianying Lou Shuguo Zheng Xinyu Bi Jianming Wang Wei Guo Fuyu Li Jian Wang Yamin Zheng Jingdong Li Shi Cheng Weiping Zhou Yongyi Zeng |
| author_sort | Lei Wang |
| collection | DOAJ |
| description | Abstract Background and Aims The prognosis of intrahepatic cholangiocarcinoma (ICC) after radical resection is far from satisfactory; however, the clinical value of adjuvant therapy (AT) remains controversial. This multicenter study aimed to evaluate the clinical value of AT and identify potential patients who would be benefited from AT. Methods Data from ICC patients who underwent radical resection were retrospectively collected from 12 hepatobiliary centers in China between December 2012 and December 2015. Patients were divided into AT and non‐AT groups based on whether AT was administered or not. Overall survival (OS) and disease‐free survival (DFS) were analyzed using the Kaplan‐Meier method before and after 1:2 propensity score matching (PSM). Subgroup analyses were conducted based on the established staging systems. Results A total of 412 patients were enrolled in this study, and 77 patients (18.9%) received AT, including 32 (7.8%) patients who received transarterial chemoembolization (TACE), 21 (5.1%) patients who received chemotherapy, 10 (2.4%) patients who received radiotherapy, and 14 (3.4%) patients who received adjuvant chemoradiotherapy. The median OS and DFS were both longer in the AT group than in the non‐AT group (43.0 months vs 21.0 months, P = .015; 16.0 months vs 11.0 months, P = .045, respectively), and the advantage of AT was confirmed for both the OS and DFS (P = .023; P = .046, respectively) after 1:2 PSM. Furthermore, based on the established nomogram, only “middle‐risk” patients receiving AT cherished a longer median OS (43.0 months vs 20.0 months, P = .033). In subgroup analyses that were stratified by different AT strategies, patients receiving postoperative chemotherapy had a longer median OS (37.0 months vs 21.0 months, P = .039), while patients receiving postoperative TACE had a longer median DFS (50.0 months vs 11.0 months, P = .007). Conclusion With the current data, we conclude that AT benefits ICC patients following radical resection, especially those “middle‐risk” patients, as evaluated by the established nomogram. However, exactly which patients are the most suitable for AT requires further study and validation. |
| format | Article |
| id | doaj-art-019ed267d1e44e5391a0545c2d5c7aac |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2020-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-019ed267d1e44e5391a0545c2d5c7aac2025-08-20T03:46:54ZengWileyCancer Medicine2045-76342020-04-01982674268510.1002/cam4.2925Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective studyLei Wang0Manjun Deng1Qiao Ke2Jianying Lou3Shuguo Zheng4Xinyu Bi5Jianming Wang6Wei Guo7Fuyu Li8Jian Wang9Yamin Zheng10Jingdong Li11Shi Cheng12Weiping Zhou13Yongyi Zeng14Department of Radiation Oncology Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou ChinaDepartment of Hepatobiliary Surgery Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou ChinaDepartment of Hepatobiliary Surgery Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou ChinaDepartment of Hepatobiliary Surgery The Second Hospital Affiliated to Zhejiang University Hangzhou ChinaDepartment of Hepatobiliary Surgery The Southwest Hospital Affiliated to the Army Medical University Chongqing ChinaDepartment of Hepatobiliary Surgery Cancer Hospital Chinese Academy of Medical Sciences Beijing ChinaDepartment of Hepatobiliary Surgery Tongji Hospital Affiliated to Tongji Medical College Huazhong University of Science & Technology Wuhan Hubei ChinaDepartment of Hepatobiliary Surgery Beijing Friendship Hospital Affiliated to Capital Medical University Beijing ChinaDepartment of Hepatobiliary Surgery The West China Hospital of Sichuan University Chengdu ChinaDepartment of Hepatobiliary Surgery Renji Hospital Affiliated to Shanghai Jiaotong University Shanghai ChinaDepartment of Hepatobiliary Surgery Xuanwu Hospital Affiliated to Capital Medical University Beijing ChinaDepartment of Hepatobiliary Surgery The Affiliated Hospital of Chuanbei Medical University Nanchong ChinaDepartment of Hepatobiliary Surgery Tiantan Hospital Affiliated to Capital Medical University Beijing ChinaDepartment of Hepatobiliary Surgery Ⅲ Eastern Hepatobiliary Surgery Hospital Secondary Military Medical University Shanghai ChinaDepartment of Radiation Oncology Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou ChinaAbstract Background and Aims The prognosis of intrahepatic cholangiocarcinoma (ICC) after radical resection is far from satisfactory; however, the clinical value of adjuvant therapy (AT) remains controversial. This multicenter study aimed to evaluate the clinical value of AT and identify potential patients who would be benefited from AT. Methods Data from ICC patients who underwent radical resection were retrospectively collected from 12 hepatobiliary centers in China between December 2012 and December 2015. Patients were divided into AT and non‐AT groups based on whether AT was administered or not. Overall survival (OS) and disease‐free survival (DFS) were analyzed using the Kaplan‐Meier method before and after 1:2 propensity score matching (PSM). Subgroup analyses were conducted based on the established staging systems. Results A total of 412 patients were enrolled in this study, and 77 patients (18.9%) received AT, including 32 (7.8%) patients who received transarterial chemoembolization (TACE), 21 (5.1%) patients who received chemotherapy, 10 (2.4%) patients who received radiotherapy, and 14 (3.4%) patients who received adjuvant chemoradiotherapy. The median OS and DFS were both longer in the AT group than in the non‐AT group (43.0 months vs 21.0 months, P = .015; 16.0 months vs 11.0 months, P = .045, respectively), and the advantage of AT was confirmed for both the OS and DFS (P = .023; P = .046, respectively) after 1:2 PSM. Furthermore, based on the established nomogram, only “middle‐risk” patients receiving AT cherished a longer median OS (43.0 months vs 20.0 months, P = .033). In subgroup analyses that were stratified by different AT strategies, patients receiving postoperative chemotherapy had a longer median OS (37.0 months vs 21.0 months, P = .039), while patients receiving postoperative TACE had a longer median DFS (50.0 months vs 11.0 months, P = .007). Conclusion With the current data, we conclude that AT benefits ICC patients following radical resection, especially those “middle‐risk” patients, as evaluated by the established nomogram. However, exactly which patients are the most suitable for AT requires further study and validation.https://doi.org/10.1002/cam4.2925adjuvant therapydisease‐free survivalintrahepatic cholangiocarcinomaoverall survivalpropensity score matching |
| spellingShingle | Lei Wang Manjun Deng Qiao Ke Jianying Lou Shuguo Zheng Xinyu Bi Jianming Wang Wei Guo Fuyu Li Jian Wang Yamin Zheng Jingdong Li Shi Cheng Weiping Zhou Yongyi Zeng Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study Cancer Medicine adjuvant therapy disease‐free survival intrahepatic cholangiocarcinoma overall survival propensity score matching |
| title | Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study |
| title_full | Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study |
| title_fullStr | Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study |
| title_full_unstemmed | Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study |
| title_short | Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study |
| title_sort | postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma a multicenter retrospective study |
| topic | adjuvant therapy disease‐free survival intrahepatic cholangiocarcinoma overall survival propensity score matching |
| url | https://doi.org/10.1002/cam4.2925 |
| work_keys_str_mv | AT leiwang postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT manjundeng postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT qiaoke postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT jianyinglou postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT shuguozheng postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT xinyubi postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT jianmingwang postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT weiguo postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT fuyuli postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT jianwang postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT yaminzheng postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT jingdongli postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT shicheng postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT weipingzhou postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy AT yongyizeng postoperativeadjuvanttherapyfollowingradicalresectionforintrahepaticcholangiocarcinomaamulticenterretrospectivestudy |